logo
  

Stock Alert: Corvus Rise 30% On Positive Data From Early COVID Treatment Study

Shares of Corvus Pharmaceuticals, Inc. (CRVS) jumped nearly 30% on Monday morning after the drug maker reported positive results from an early stage study of investigational COVID-19 treatment.

CRVS is currently trading at $5.20, up $1.13 or 27.76%, on the Nasdaq.

The clinical-stage biopharmaceutical company said that new data from phase 1 study of CPI-006, which is intended to improve immune system by producing anti-SARS-CoV-2 antibodies, continues to support its potential as a treatment for COVID-19.

The results showed increased levels of memory B cells and memory T cells, and there have been no reports of any drug-related safety issues in any of the 15 patients treated as of September 17.

"We continue to see consistent, promising results with CPI-006 in hospitalized COVID-19 patients...We are also exploring the potential use in combination with preventative vaccines under development by third parties to enhance and prolong immunity," said Richard Miller,, president and chief executive officer of Corvus.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Asweets Global Inc. is recalling about 2,000 units of Wonder & Wise Activity Tables for potential risk of choking hazard to young children, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said the screws of the tables can become loose and/or detach from the xylophone component of the activity tables to pose a choking hazard to young children. Chinese e-commerce giant Alibaba Group Holdings Ltd. (BABA) reported Thursday a net loss for the fourth quarter that sharply widened from last year, despite 9 percent growth in revenues, hurt by a decreases in the market prices of our equity investments in publicly-traded companies. Omni-channel fashion retailer Macy's, Inc. (M) reported Thursday a first-quarter net income of $286 million or $0.98 per share, sharply higher than $103 million or $0.32 per share in the prior-year quarter. Excluding items, adjusted net income for the quarter was $315 million or $1.08 per share, compared...
Follow RTT